Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Security

Apollomics Inc. Warrant · APLMW

APLMWNASDAQWarrantCurrentCIK 1944885Updated Nov 18, 2026

Company: Apollomics Inc. →

APLMW price & chart

Provider market data

Loading TradingView…

NASDAQ:APLMW on TradingView ↗

TradingView · Data may be delayed

About the company

Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics’ lead program is vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States and other countries.

6-K · 2026-08-12 · 0001193125-26-345197

Company description from the cited filing.

In the news

No coverage from other publishers is available.

SEC disclosures

Recent filings

  1. 6-K filing

    6-K · 2026-11-06 · 0001193125-26-451861

  2. 424B3 filing

    424B3 · 2026-09-08 · 0001193125-26-384280

  3. D filing

    Items 06b

    D · 2026-08-19 · 0001193125-26-355924

  4. SCHEDULE 13D/A - filed by Chen Yi-Kuei regarding Apollomics Inc.

    SCHEDULE 13D/A · 2026-08-14 · 0001213900-26-090085

  5. 6-K filing

    6-K · 2026-08-12 · 0001193125-26-345197

Show 5 more recent filings
  1. 6-K filing

    6-K · 2026-07-21 · 0001193125-26-310154

  2. 6-K filing

    6-K · 2026-07-14 · 0001193125-26-302494

  3. 6-K filing

    6-K · 2026-06-24 · 0001193125-26-281262

  4. 4 filing

    4 · 2026-06-16 · 0001193125-26-272821

  5. EFFECT filing

    EFFECT · 2026-06-02 · 9999999995-26-001838

Financials

FY 2024 · USD
Net income— · FY 2024
Assets—USD · FY 2024
Cash— · FY 2024
Operating income— · FY 2024
Diluted EPS-52.8USD per share · FY 2024
Source

20-F · 2025-04-03 · 0000950170-25-050531

2024-01-01 to 2024-12-31

Some figures are unavailable for this reporting year.

Balance-sheet figures are unavailable pending verification.

cash flow · annual statements
Line itemQ2 2023FY 2024FY 2023FY 2022FY 2021
Cash flows from operating activities:
Profit or LossUSD—-53,858,000
Source

20-F · 2025-04-03 · 0000950170-25-050531

2024-01-01 to 2024-12-31

-172,601,000
Source

20-F · 2024-03-28 · 0000950170-24-038107

2023-01-01 to 2023-12-31

-240,811,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2022-01-01 to 2022-12-31

-94,797,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2021-01-01 to 2021-12-31

Cash flows from financing activities:
Dividends paid——
Source

20-F · 2025-04-03 · 0000950170-25-050531

2024-01-01 to 2024-12-31

—
Source

20-F · 2024-03-28 · 0000950170-24-038107

2023-01-01 to 2023-12-31

—
Source

20-F · 2023-04-28 · 0001193125-23-127602

2022-01-01 to 2022-12-31

—
Source

20-F · 2023-04-28 · 0001193125-23-127602

2021-01-01 to 2021-12-31

Additional Financial Items
AdjustmentsForCurrentTaxOfPriorPeriodUSD—0
Source

20-F · 2025-04-03 · 0000950170-25-050531

2024-01-01 to 2024-12-31

0
Source

20-F · 2024-03-28 · 0000950170-24-038107

2023-01-01 to 2023-12-31

0
Source

20-F · 2023-04-28 · 0001193125-23-127602

2022-01-01 to 2022-12-31

0
Source

20-F · 2023-04-28 · 0001193125-23-127602

2021-01-01 to 2021-12-31

AdjustmentsForFinanceCostsUSD—193,000
Source

20-F · 2025-04-03 · 0000950170-25-050531

2024-01-01 to 2024-12-31

122,000
Source

20-F · 2024-03-28 · 0000950170-24-038107

2023-01-01 to 2023-12-31

93,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2022-01-01 to 2022-12-31

83,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2021-01-01 to 2021-12-31

AdjustmentsForSharebasedPaymentsUSD—10,926,000
Source

20-F · 2025-04-03 · 0000950170-25-050531

2024-01-01 to 2024-12-31

12,685,000
Source

20-F · 2024-03-28 · 0000950170-24-038107

2023-01-01 to 2023-12-31

3,582,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2022-01-01 to 2022-12-31

8,122,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2021-01-01 to 2021-12-31

AdjustmentsForUnrealisedForeignExchangeLossesGainsUSD——-258,000
Source

20-F · 2024-03-28 · 0000950170-24-038107

2023-01-01 to 2023-12-31

663,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2022-01-01 to 2022-12-31

—
InterestPaidClassifiedAsFinancingActivitiesUSD—193,000
Source

20-F · 2025-04-03 · 0000950170-25-050531

2024-01-01 to 2024-12-31

122,000
Source

20-F · 2024-03-28 · 0000950170-24-038107

2023-01-01 to 2023-12-31

93,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2022-01-01 to 2022-12-31

83,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2021-01-01 to 2021-12-31

InterestPaidClassifiedAsOperatingActivitiesUSD—259,000
Source

20-F · 2025-04-03 · 0000950170-25-050531

2024-01-01 to 2024-12-31

10,000
Source

20-F · 2024-03-28 · 0000950170-24-038107

2023-01-01 to 2023-12-31

1,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2022-01-01 to 2022-12-31

—
PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD—170,000
Source

20-F · 2025-04-03 · 0000950170-25-050531

2024-01-01 to 2024-12-31

444,000
Source

20-F · 2024-03-28 · 0000950170-24-038107

2023-01-01 to 2023-12-31

593,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2022-01-01 to 2022-12-31

528,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2021-01-01 to 2021-12-31

ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivitiesUSD—4,000
Source

20-F · 2025-04-03 · 0000950170-25-050531

2024-01-01 to 2024-12-31

58,000
Source

20-F · 2024-03-28 · 0000950170-24-038107

2023-01-01 to 2023-12-31

——
PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesUSD————7,500,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2021-01-01 to 2021-12-31

Goodwill—
Source

6-K · 2023-09-28 · 0000950170-23-050420

As of 2023-06-30

————

Lines labelled “Derived” are calculated from reported figures.

income statement · annual statements
Line itemFY 2024FY 2023FY 2022FY 2021
Total RevenueUSD0
Source

20-F · 2025-04-03 · 0000950170-25-050531

2024-01-01 to 2024-12-31

0
Source

20-F · 2024-03-28 · 0000950170-24-038107

2023-01-01 to 2023-12-31

0
Source

20-F · 2023-04-28 · 0001193125-23-127602

2022-01-01 to 2022-12-31

0
Source

20-F · 2023-04-28 · 0001193125-23-127602

2021-01-01 to 2021-12-31

Additional Financial Items
AdministrativeExpenseUSD17,768,000
Source

20-F · 2025-04-03 · 0000950170-25-050531

2024-01-01 to 2024-12-31

20,641,000
Source

20-F · 2024-03-28 · 0000950170-24-038107

2023-01-01 to 2023-12-31

9,947,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2022-01-01 to 2022-12-31

15,291,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2021-01-01 to 2021-12-31

BasicEarningsLossPerShareUSD per share-52.8
Source

20-F · 2025-04-03 · 0000950170-25-050531

2024-01-01 to 2024-12-31

-2.32
Source

20-F · 2024-03-28 · 0000950170-24-038107

2023-01-01 to 2023-12-31

-0.62
Source

20-F · 2023-04-28 · 0001193125-23-127602

2022-01-01 to 2022-12-31

-0.23
Source

20-F · 2023-04-28 · 0001193125-23-127602

2021-01-01 to 2021-12-31

CurrentTaxExpenseIncomeUSD259,000
Source

20-F · 2025-04-03 · 0000950170-25-050531

2024-01-01 to 2024-12-31

10,000
Source

20-F · 2024-03-28 · 0000950170-24-038107

2023-01-01 to 2023-12-31

1,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2022-01-01 to 2022-12-31

1,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2021-01-01 to 2021-12-31

DeferredTaxExpenseIncomeUSD0
Source

20-F · 2025-04-03 · 0000950170-25-050531

2024-01-01 to 2024-12-31

0
Source

20-F · 2024-03-28 · 0000950170-24-038107

2023-01-01 to 2023-12-31

0
Source

20-F · 2023-04-28 · 0001193125-23-127602

2022-01-01 to 2022-12-31

0
Source

20-F · 2023-04-28 · 0001193125-23-127602

2021-01-01 to 2021-12-31

DeferredTaxExpenseIncomeRecognisedInProfitOrLossUSD0
Source

20-F · 2025-04-03 · 0000950170-25-050531

2024-01-01 to 2024-12-31

0
Source

20-F · 2024-03-28 · 0000950170-24-038107

2023-01-01 to 2023-12-31

0
Source

20-F · 2023-04-28 · 0001193125-23-127602

2022-01-01 to 2022-12-31

0
Source

20-F · 2023-04-28 · 0001193125-23-127602

2021-01-01 to 2021-12-31

DepreciationRightofuseAssetsUSD289,000
Source

20-F · 2025-04-03 · 0000950170-25-050531

2024-01-01 to 2024-12-31

587,000
Source

20-F · 2024-03-28 · 0000950170-24-038107

2023-01-01 to 2023-12-31

593,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2022-01-01 to 2022-12-31

528,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2021-01-01 to 2021-12-31

DilutedEarningsLossPerShareUSD per share-52.8
Source

20-F · 2025-04-03 · 0000950170-25-050531

2024-01-01 to 2024-12-31

-2.32
Source

20-F · 2024-03-28 · 0000950170-24-038107

2023-01-01 to 2023-12-31

-0.62
Source

20-F · 2023-04-28 · 0001193125-23-127602

2022-01-01 to 2022-12-31

-0.23
Source

20-F · 2023-04-28 · 0001193125-23-127602

2021-01-01 to 2021-12-31

EmployeeBenefitsExpenseUSD19,556,000
Source

20-F · 2025-04-03 · 0000950170-25-050531

2024-01-01 to 2024-12-31

23,540,000
Source

20-F · 2024-03-28 · 0000950170-24-038107

2023-01-01 to 2023-12-31

19,210,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2022-01-01 to 2022-12-31

27,742,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2021-01-01 to 2021-12-31

ExpenseFromSharebasedPaymentTransactionsWithEmployeesUSD10,926,000
Source

20-F · 2025-04-03 · 0000950170-25-050531

2024-01-01 to 2024-12-31

12,685,000
Source

20-F · 2024-03-28 · 0000950170-24-038107

2023-01-01 to 2023-12-31

3,582,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2022-01-01 to 2022-12-31

8,122,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2021-01-01 to 2021-12-31

ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsedUSD67,000
Source

20-F · 2025-04-03 · 0000950170-25-050531

2024-01-01 to 2024-12-31

122,000
Source

20-F · 2024-03-28 · 0000950170-24-038107

2023-01-01 to 2023-12-31

96,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2022-01-01 to 2022-12-31

56,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2021-01-01 to 2021-12-31

FinanceCostsUSD179,000
Source

20-F · 2025-04-03 · 0000950170-25-050531

2024-01-01 to 2024-12-31

150,000
Source

20-F · 2024-03-28 · 0000950170-24-038107

2023-01-01 to 2023-12-31

93,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2022-01-01 to 2022-12-31

83,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2021-01-01 to 2021-12-31

ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillUSD13,000,000
Source

20-F · 2025-04-03 · 0000950170-25-050531

2024-01-01 to 2024-12-31

0
Source

20-F · 2024-03-28 · 0000950170-24-038107

2023-01-01 to 2023-12-31

0
Source

20-F · 2023-04-28 · 0001193125-23-127602

2022-01-01 to 2022-12-31

3,000,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2021-01-01 to 2021-12-31

IncomeTaxExpenseContinuingOperationsUSD259,000
Source

20-F · 2025-04-03 · 0000950170-25-050531

2024-01-01 to 2024-12-31

10,000
Source

20-F · 2024-03-28 · 0000950170-24-038107

2023-01-01 to 2023-12-31

1,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2022-01-01 to 2022-12-31

1,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2021-01-01 to 2021-12-31

InterestExpenseOnLeaseLiabilitiesUSD179,000
Source

20-F · 2025-04-03 · 0000950170-25-050531

2024-01-01 to 2024-12-31

150,000
Source

20-F · 2024-03-28 · 0000950170-24-038107

2023-01-01 to 2023-12-31

93,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2022-01-01 to 2022-12-31

83,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2021-01-01 to 2021-12-31

OtherIncomeUSD1,489,000
Source

20-F · 2025-04-03 · 0000950170-25-050531

2024-01-01 to 2024-12-31

1,217,000
Source

20-F · 2024-03-28 · 0000950170-24-038107

2023-01-01 to 2023-12-31

1,447,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2022-01-01 to 2022-12-31

1,054,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2021-01-01 to 2021-12-31

PostemploymentBenefitExpenseDefinedBenefitPlansUSD300,000
Source

20-F · 2025-04-03 · 0000950170-25-050531

2024-01-01 to 2024-12-31

499,000
Source

20-F · 2024-03-28 · 0000950170-24-038107

2023-01-01 to 2023-12-31

662,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2022-01-01 to 2022-12-31

749,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2021-01-01 to 2021-12-31

ProfitLossBeforeTaxUSD-53,599,000
Source

20-F · 2025-04-03 · 0000950170-25-050531

2024-01-01 to 2024-12-31

-172,591,000
Source

20-F · 2024-03-28 · 0000950170-24-038107

2023-01-01 to 2023-12-31

-240,810,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2022-01-01 to 2022-12-31

-94,796,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2021-01-01 to 2021-12-31

ProfitLossFromOperatingActivitiesUSD——976,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2022-01-01 to 2022-12-31

—
ResearchAndDevelopmentExpenseUSD24,566,000
Source

20-F · 2025-04-03 · 0000950170-25-050531

2024-01-01 to 2024-12-31

34,193,000
Source

20-F · 2024-03-28 · 0000950170-24-038107

2023-01-01 to 2023-12-31

35,457,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2022-01-01 to 2022-12-31

35,568,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2021-01-01 to 2021-12-31

RevenueFromInterestUSD480,000
Source

20-F · 2025-04-03 · 0000950170-25-050531

2024-01-01 to 2024-12-31

753,000
Source

20-F · 2024-03-28 · 0000950170-24-038107

2023-01-01 to 2023-12-31

431,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2022-01-01 to 2022-12-31

467,000
Source

20-F · 2023-04-28 · 0001193125-23-127602

2021-01-01 to 2021-12-31

Lines labelled “Derived” are calculated from reported figures.

Offerings

Registration 333-294154

F-3/A · 2026-05-15 · 0001193125-26-226827

Terms from the governing filing for this registration; not a claim that the offering is open today.

Filing attachments

aplm-ex99_1.htm · 6-K · 2026-11-06

Exhibit 99.1 INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Unaudited Condensed Consolidated Interim Statements of Financial Position as of June 30, 2026 and December 31, 2025 1 Unaudited Condensed Consolidated Interim Statements of Operations and Comprehensive Loss for the Six Months Ended June 30, 2026 and 2025 2 Unaudited Condensed Consolidated Interim Statements of Shareholders’ Equity (Deficit) for the Six Months Ended June 30…

6-K · 2026-11-06 · 0001193125-26-451861

Read attachment ↗
aplm-ex99_2.htm · 6-K · 2026-11-06

Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our financial condition and results of operations (the “MD&A”) should be read together with the unaudited condensed consolidated interim financial statements and the related notes to those statements included as Exhibit 99.1 to this Report on Form 6-K submitted to the Securities and Exchange Commission, or the SEC, on November 6, 2026. We also recommend th…

6-K · 2026-11-06 · 0001193125-26-451861

Read attachment ↗
d133013dex991.htm · 6-K · 2026-08-12

Exhibit 99.1 Apollomics Announces $10 Million Private Placement Transaction FOSTER CITY, CALIF. - August 11, 2026 - Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that it has entered into definitive subscription agreements (the “Subscription Agreements”) for a private placement transaction (the “Private Plac…

6-K · 2026-08-12 · 0001193125-26-345197

Read attachment ↗
d31896dex991.htm · 6-K · 2026-07-14

Exhibit 99.1 Apollomics Regains Full Compliance with Nasdaq Listing Requirements FOSTER CITY, CALIF. - July 13, 2026 - Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that on July 8, 2026, it received written notice from the Nasdaq Listing Qualifications Staff (Staff) stating that the Company regained complia…

6-K · 2026-07-14 · 0001193125-26-302494

Read attachment ↗
d137400dex991.htm · 6-K · 2026-06-24

Exhibit 99.1 Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia FOSTER CITY, CALIF. - June 24, 2026 - Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that it has received a notice (the “Notice”) from The Nasdaq Stock Ma…

6-K · 2026-06-24 · 0001193125-26-281262

Read attachment ↗
aplm-ex99_1.htm · 6-K · 2026-04-27

Exhibit 99.1 Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress ▪ Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential. ▪ To date, more than 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials. ▪ Phase 2/3 IND submission for development of vebreltinib in combination with an E…

6-K · 2026-04-27 · 0001193125-26-179094

Read attachment ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.